

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

Search

[About Memorial Sloan Kettering Cancer Center](#)

[About Cancer & Treatment](#)

What can we help you find today?

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Eileen M. O'Reilly, MD

[Gastrointestinal Medical Oncologist](#) ([#about-me](#))



Areas of Expertise

Conditions I Treat

- Pancreatic cancer
- Pancreatic neuroendocrine tumors
- Gallbladder cancer

My Specialties

- Immunotherapy
- Clinical trials

[View more expertise](#) ([#about_specialties](#))



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

[Call 646-497-9053](#)

[Make an appointment](#)

Get to Know Me

I am a medical oncologist who cares for people with pancreatic and hepatobiliary (hep-uh-toh-BIL-ee-air-ee) cancers, including:

- [Pancreatic cancer](#)
- [Liver cancer](#)
- [Bile duct cancer \(cholangiocarcinoma\)](#)
- [Gallbladder cancer](#)
- Other gastrointestinal cancers

At Memorial Sloan Kettering Cancer Center (MSK), I work closely with a team of experts across medical areas. These include:

- [Surgery](#)
- Medical oncology
- [Gastroenterology](#)
- [Radiation](#) oncology
- [Integrative medicine](#)
- [Social work](#)

Together, we create a care plan that best treats each person's cancer while honoring their personal wants and needs for cancer treatment. To achieve these goals, I communicate clearly and effectively with every patient, their family, and other team members. I strive for excellence in these areas as part of my commitment to offer the best possible care.

What I Do at MSK

I'm a gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist, which is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers. We also treat GI stromal tumors and neuroendocrine tumors.

- Winthrop Rockefeller Endowed Chair of Medical Oncology
- Chair, Human Research Protection Program and Institutional Review Board
- Co-Director, Medical, David M. Rubenstein Center for Pancreatic Cancer Research
- Section Head, HPB & Neuroendocrine Cancers

Areas of Expertise

Conditions I Treat

- Pancreatic cancer
- Pancreatic neuroendocrine tumors
- Gallbladder cancer
- Bile duct cancer (cholangiocarcinoma)
- Primary liver cancer

My Specialties

- Immunotherapy
- Clinical trials

Education & Honors

Education

- MD, Trinity College, Ireland

Residencies

- Internal Medicine - St. James's Hospital

Fellowships

- Internal Medicine/Medical Oncology - St. Vincent's Hospital (Ireland)
- Medical Oncology - Memorial Sloan Kettering Cancer Center
- Medicine - Cornell University Medical Center

Board Certifications

- Internal Medicine (Ireland)

Awards and Honors

- Castle Connolly: America's Top Doctor (2005-2026)
- Whitman Award for Clinical Excellence (2025)
- Castle Connolly: Exceptional Women in Medicine (2019-2026)
- Fellow of the American Society of Clinical Oncology (2024)
- Top Doctors New York Metro Area, Castle Connolly (2005-2023)
- Giant of Cancer Care, Gastrointestinal Cancer, OncLive (2023)
- New York Magazine Top Doctors (2005-2025)
- Burkitt Medal (TCD)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176) .

Make an Appointment

New Patients

Scheduling an appointment is easy. Click or call [646-497-9053](tel:646-497-9053) — we're available 24 hours a day, 7 days a week

[Make an Appointment](#)

Current Patients

Request an appointment by calling your Care Team or messaging them in [MSK MyChart](#).

Contact and Location


Office Phone

 [646-888-4182](tel:646-888-4182)

Location

 New York, NY

[Rockefeller Outpatient Pavilion](#)

 160 East 53rd Street
New York, NY 10022

[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .


Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Gastrointestinal Oncology Service doctors. \(https://www.mskcc.org/doctor?field_vocab_departments%5B813%5D=813\)](https://www.mskcc.org/doctor?field_vocab_departments%5B813%5D=813)

Clinical Trials

- Clinical Trials Investigated by Dr. O'Reilly
- [A Phase 1 Study of INCB161734 in People With Solid Tumors](#)
- [A Phase 1-2 Study of TNG462 Plus Other Medications in People With Pancreatic or Non-Small Cell Lung Cancer](#)
- [A Phase 1b Study of AMG 193 Plus mFOLFIRINOX or With Gemcitabine and Nab-paclitaxel in People With Advanced Pancreatic Cancer](#)
- [A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma](#)



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials \(https://www.mskcc.org/cancer-care/clinical-trials\)](https://www.mskcc.org/cancer-care/clinical-trials)

Research and Publications

O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfield C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM; RASolute 302 Trial Investigators. [Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer](#) . *N Engl J Med*. 2026 May 31.

doi: 10.1056/NEJMoa2605555. Epub ahead of print. PMID: 42223072.

Park W, O'Connor CA, Iacobuzio-Donahue C, O'Reilly EM. [Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial](#) . *Nat Med*. 2026 Mar 25. Epub ahead of print. PMID: 41882405.

Wainberg ZA, Weekes CD, Haqq CM, Pant S, O'Reilly EM. [Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results](#) . *Nat Med*. 2025 Nov;31(11):3648-3653. Epub 2025 Aug 11. PMID: 40790272; PMCID: PMC12618236.

Varghese AM, Perry MA, Bandlamudi C, O'Reilly EM. [Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival](#) . *Nat Med*. 2025 Feb;31(2):466-477. Epub 2025 Jan 3. PMID: 39753968; PMCID: PMC11835752.

Publications on PubMed

Visit PubMed for a full listing of Dr. O'Reilly's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed \(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28%28%22neoplasms%22%5BMH%5D%20OR%20cancer%5BTW%5D%29%20OR%20sloan-kettering%20AND%20%27Reilly%20E%5BAU%5D%20NOT%20O%27Reilly%20EK%5BAU%5D%29\)](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28%28%22neoplasms%22%5BMH%5D%20OR%20cancer%5BTW%5D%29%20OR%20sloan-kettering%20AND%20%27Reilly%20E%5BAU%5D%20NOT%20O%27Reilly%20EK%5BAU%5D%29)

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Eileen M. O'Reilly discloses the following relationships and financial interests:

- AbbVie
Professional Services and Activities (Uncompensated)
- American Society of Clinical Oncology (ASCO)
Professional Services and Activities
- AstraZeneca
Professional Services and Activities (Uncompensated)
- AUTEM Medical, LLC
Professional Services and Activities (Uncompensated)

- Boehringer Ingelheim
Professional Services and Activities (Uncompensated)
- HMP Oncology Learning Network
Professional Services and Activities

- Imedex, Inc.
Professional Services and Activities
- Research to Practice
Professional Services and Activities
- Revolution Medicines
Professional Services and Activities (Uncompensated)
- Syros Pharmaceuticals, Inc.
Professional Services and Activities (Uncompensated)
- Tango Therapeutics
Professional Services and Activities

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center